Development asset linked to Yung Shin Pharmaceutical in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.
- Mechanism
- HMG-CoA reductase inhibitor
pharma · Hypertension · Gastric Ulcer
Yung Shin Pharmaceutical
Yung NA
Yung Shin Pharmaceutical drug portfolio — 13 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Taichung, CN HQ
1952 Founded
264 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Taichung, CN
- Founded
- 1952
- Employees
- 264
- Programs
- 10
- Drugs
- 13
- Patents
- 0
Yung Shin Pharmaceutical pipeline
Portfolio lens on 13 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Yung Shin Pharmaceutical drug portfolio — 13 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Yung Shin Pharmaceutical in public FDA and regional records.
-
Development asset linked to Yung Shin Pharmaceutical in public FDA and regional records. Molecular target: Prothrombin.
- Target
- Prothrombin
- Mechanism
- Thrombin inhibitor
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
pregabalin
Nervous system (N02)US regulatory status: approved. Molecular target: Voltage-gated calcium channel.
- Target
- Voltage-gated calcium channel
- Mechanism
- Voltage-gated calcium channel modulator
-
Development asset linked to Yung Shin Pharmaceutical in public FDA and regional records. Mechanism: Potassium-transporting ATPase inhibitor.
- Mechanism
- Potassium-transporting ATPase inhibitor
-
US regulatory status: approved. Molecular target: Potassium-transporting ATPase.
- Target
- Potassium-transporting ATPase
- Mechanism
- Potassium-transporting ATPase inhibitor
-
Development asset linked to Yung Shin Pharmaceutical in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.
- Mechanism
- HMG-CoA reductase inhibitor
-
ruxolitinib
Dermatologicals (D11)US regulatory status: approved. Mechanism: Tyrosine-protein kinase JAK2 inhibitor.
- Mechanism
- Tyrosine-protein kinase JAK2 inhibitor
-
Development asset linked to Yung Shin Pharmaceutical in public FDA and regional records.
-
Development asset linked to Yung Shin Pharmaceutical in public FDA and regional records.
-
Development asset linked to Yung Shin Pharmaceutical in public FDA and regional records.